Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2016
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphomaXuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, et al.
Blood Cancer Journal|May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
British Journal of Haematology|December 22, 2017
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysisNirav N Shah, Aniko Szabo, Scott F Huntington, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative StudyMohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
JAMA Oncology|March 1, 2019
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMTAbraham S Kanate, Ambuj Kumar, Peter Dreger, et al.
Blood Advances|August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationNarendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Pageof 6